---
canonical_url: https://www.stockexpertai.com/zh/earnings/vrtx
last_updated: 2026-05-03T21:46:03.333Z
---

# Vertex Pharmaceuticals Incorporated (VRTX) Q4 FY2026 财报预览

> **[stale-preview-note]** 注：本预览发布于2026-05-04财报之前。请以最新公告为准。

> 此内容由 FMP 实时数据 + Q4 FY2025 财报电话会议记录自动生成。生成时间：2026-05-03T21:46:02.570Z。本工具为教育目的，不构成投资建议。

---

## 快速摘要

| 字段 | 值 | 来源 |
|---|---|---|
| 价格 | $423.92 (▼ -0.81%) | fmp:quote |
| 市值 | $107.8B | fmp:profile |
| 52周区间 | $362.50 – $507.92 | fmp:quote |
| 财报 | 周一 4 5月 | fmp:earnings-history |
| EPS 预期 | $4.23 (+4% YoY) | fmp:earnings-estimate |
| 营收预期 | $3.0B | fmp:earnings-estimate |
| 超预期连胜 | 0/4 | fmp:earnings-history |
| 评级 | B+ (overall 3/5) | fmp:ratings |
| 分析师中位数目标价 | $558 (+31.6% upside) | fmp:price-target-consensus |
| MoonshotScore | 66/100 | derived |
| Council | 4/6 bullish | derived |
| 芒格结论 | 低估 | derived |

## Vertex Pharmaceuticals Incorporated — Q4 FY2026 预期

Q4 季度共识：营收 <strong data-source="fmp:earnings-estimate" data-field="estimates.next.revenueAvgLabel">$3.0B</strong><sup class="cite" data-source="fmp:earnings-estimate" data-field="estimates.next.revenueAvg" title="FMP est">[FMP est]</sup>，EPS <strong data-source="fmp:earnings-estimate" data-field="estimates.next.epsAvg">$4.23</strong><sup class="cite" data-source="fmp:earnings-estimate" data-field="estimates.next.epsAvg" title="FMP est">[FMP est]</sup>。连续 0 个季度超出预期<sup class="cite" data-source="fmp:earnings-history" data-field="earnings.beatStreakCount" title="FMP earnings">[FMP earnings]</sup>。

## 快速概览

**得分：** B+ · **立场：** BUY · **Council：** 4/6 · **Moonshot：** 66

= MoonshotScore <strong>66</strong><sup class="cite" data-source="derived" data-field="moonshot.score" title="MoonshotScore">[MoonshotScore]</sup> + Council <strong>4/6</strong><sup class="cite" data-source="derived" data-field="council.bullishCount" title="Council">[Council]</sup>。Form 4: 0 笔交易<sup class="cite" data-source="fmp:insider-trading" data-field="insider.txCount" title="FMP Form 4">[FMP Form 4]</sup>。

## 观察列表 (5个指标)

### 1. Effective Tax Rate Guidance

Vertex 预计 2026 年其非 GAAP 有效税率将在 19.5% 至 20.5% 之间。

> "我们预计 2026 年的非 GAAP 有效税率将在 19.5% 至 20.5% 之间，因为我们预计 2025 年的一次性税收优惠不会重现。"
> — Charles Wagner, Chief Operating Officer and Chief Financial Officer, Expectation / Guide · Q4 FY2025

### 2. 2026 Revenue Growth

Vertex 预计 2026 年公司总收入增长 8% 至 9%。

> "我们预计 2026 年全年公司总收入将在 129.5 亿美元至 131 亿美元之间，较上年增长 8% 至 9%。"
> — Charles Wagner, Chief Operating Officer and Chief Financial Officer, Investor Focus · Q4 FY2025

### 3. Operating Expense Guidance

Vertex 预计 2026 年合并后的非 GAAP 运营费用将在 56.5 亿美元至 57.5 亿美元之间。

> "此外，我们预计合并后的非 GAAP 运营费用将在 56.5 亿美元至 57.5 亿美元之间，因为我们将继续投资于我们的后期临床产品线和商业建设，以支持新产品的发布和收入多元化，特别是 JOURNAVX 在急性疼痛和肾脏疾病方面的应用。"
> — Charles Wagner, Chief Operating Officer and Chief Financial Officer, Expectation / Guide · Q4 FY2025

### 4. Non CF Revenue Contribution

Vertex 预计 2026 年非 CF 产品将贡献 5 亿美元或更多的收入。

> "这一展望预计我们的 CF 业务将继续保持稳健表现，非 CF 产品将贡献 5 亿美元或更多的收入，其中包括 CASGEVY 患者输液量的增加和 JOURNAVX 处方量的增加。"
> — Charles Wagner, Chief Operating Officer and Chief Financial Officer, Investor Focus · Q4 FY2025

### 5. Journavx Prescription Growth

Vertex 预计 2026 年 JOURNAVX 处方量将比 2025 年增加两倍以上。

> "2026 年，我们预计 JOURNAVX 处方量将比 2025 年的约 55 万张增加两倍以上。"
> — Duncan J. McKechnie, Chief Commercial Officer, Investor Focus · Q4 FY2025


## MoonshotScore 支柱

| 支柱 | 得分 | 水平 | 证据 |
|---|---|---|---|
| 营收增长 | 8.0 | strong | Q4 vs Q1: 快速增长 (+%16.5) |
| 毛利率 | 9.0 | strong | Q4: 极高毛利率 (%85.6，软件/云服务级别) |
| 经营杠杆 | 4.0 | medium | 营业利润率非常强劲 (%40.3，规模杠杆) |
| 现金流储备 | 10.0 | strong | FCF 非常强劲 ($0.3B，是资本支出的 2.3 倍以上) |
| 研发投入强度 | 3.0 | weak | 极高研发投入 (%32.9，存在利润率压力风险) |
| 价格动能 | 4.0 | medium | RSI 38.7 动能疲弱，50日均线 之下 |
| 新闻情绪 | 8.0 | strong | 强烈买入共识 (81%) |

**公式:** sum(pillar.score) / (count * 10) * 100. Each pillar deterministic from FMP. Source maps in pillar.formula.

## Council (7视角)

| 名称 | 立场 | 背景 |
|---|---|---|
| Ray Dalio | bull | 宏观 · 目标上涨空间 +31.6% |
| Ken Griffin | bear | 资金流 · 50日均线 之下 |
| Jim Simons | neutral | 量化 · RSI 39 |
| Klarman | bull | 价值 · 目标上涨空间 +31.6% |
| Buffett | bull | 质量 · ROE 评分 5/5 |
| Munger | bull | 估值 · 目标上涨空间 +31.6% |

**公式:** Each lens uses deterministic rule on bundle data. Logged in member.contextTr.

## 芒格视角

- **结论:** 低估
- **财务健康:** Moderate
- **安全边际:** Strong
- **利息覆盖率:** Adequate
- **ROIC vs WACC:** Healthy

**公式:** verdict=upside>25?Undervalued:>0?Fairly Valued:Overvalued. Each lens deterministic from FMP ratings + priceTarget.

## 技术水平

- **RSI(14):** 38.7 — momentum zayıf — oversold yakınında değil ama alıcı baskısı az
- **50日均线:** $454 — hisse %6.5 altında — kısa vadeli direnç
- **200日均线:** $436 — hisse %2.8 altında — uzun vadeli baskı
- **成交量 (10日):** -13%

## 历史表现 (4个季度)

| 季度 | 实际 EPS | 预期 EPS | 结果 | 反应 |
|---|---|---|---|---|
| Q1 FY25 | $4.06 | $4.25 | MISS | -10.0% |
| Q2 FY25 | $4.52 | $4.29 | BEAT | -20.6% |
| Q3 FY25 | $4.80 | $4.57 | BEAT | -1.0% |
| Q4 FY25 | $5.03 | $5.11 | +-1.6% EPS | +5.7% |

Q4 (2026年2月12日): EPS $5.03 vs 预期 $5.11<sup class="cite" data-source="fmp:earnings-history" data-field="earnings.history.0" title="FMP">[FMP]</sup>，超出 +%-1.6。D+1 走势：+5.7%<sup class="cite" data-source="fmp:earnings-history" data-field="earnings.timeline.3.reactionLabel" title="FMP D+1">[FMP D+1]</sup>。尽管超出预期，但股价下跌 — 市场对指引而非数据做出反应。

## 3种情景

### 情景 A · 超预期
**Q4 EPS > $4.23 + 资本支出纪律**

阈值：EPS > $4.23<sup class="cite" data-source="fmp:earnings-estimate" data-field="estimates.next.epsAvg">[FMP est]</sup>。

目标：突破中位数目标价 $558<sup class="cite" data-source="fmp:price-target-consensus" data-field="priceTarget.median">[FMP target]</sup>；高目标价 $612<sup class="cite" data-source="fmp:price-target-consensus" data-field="priceTarget.high">[FMP]</sup> 为上限。

### 情景 B · 符合预期
**EPS ≈ $4.23 + CapEx < $149.4M**

阈值：EPS ≈ $4.23<sup class="cite" data-source="fmp:earnings-estimate" data-field="estimates.next.epsAvg">[FMP est]</sup>，Q4 资本支出 < $149.4M<sup class="cite" data-source="fmp:cashflow" data-field="cashflow.qPrev.capexLabel">[FMP]</sup>。

目标：在当前价 $424<sup class="cite" data-source="fmp:quote" data-field="quote.price">[FMP]</sup> 与中位数目标价 $558<sup class="cite" data-source="fmp:price-target-consensus" data-field="priceTarget.median">[FMP]</sup> 区间内盘整。

### 情景 C · 未达预期
**EPS < $4.10 或 CapEx ≥ $149.4M**

阈值：EPS < $4.10<sup class="cite" data-source="fmp:earnings-estimate" data-field="estimates.next.epsAvg">[FMP est×0.97]</sup>。

目标：当前价 $424 低于 200日均线 $436<sup class="cite" data-source="fmp:technical" data-field="technical.sma200">[FMP]</sup>，若持续拒绝，则激活 $371<sup class="cite" data-source="derived" data-field="technical.sma200" data-formula="round(sma200*0.85)">[derived]</sup> 支撑位。

## 风险提示

### {{segment}} 低于阈值
Q4 季度：EPS $5.03 vs 预期 $5.11<sup class="cite" data-source="fmp:earnings-history" data-field="earnings.history.0" title="FMP">[FMP]</sup>，超出预期，股价 D+1 +5.7%<sup class="cite" data-source="fmp:earnings-history" data-field="earnings.timeline.3.reactionLabel" title="FMP">[FMP]</sup>。

### 对 OpenAI 的依赖
Q4 财报电话会议中未披露 RPO/积压集中度。

### 内幕交易
Form 4 数据已在表格中标记 — 本页面不为此股票生成假设。

| 高管 | 操作 | 金额 | 日期 |
|---|---|---|---|


**净额:** — (0 笔交易 · 0 笔卖出 · 0 笔买入) · Q4 FY25

### 资本支出冲击
Q4 季度资本支出 $149.4M<sup class="cite" data-source="fmp:cashflow" data-field="cashflow.qPrev.capexLabel" title="FMP cashflow">[FMP cashflow]</sup>。 Q4 营业利润率 %40.3<sup class="cite" data-source="fmp:income" data-field="income.quarters.0.operatingMargin" title="FMP op margin">[FMP op margin]</sup> — Q4 的这一水平对资本支出修订风险敏感。

## 华尔街共识

- **中位数目标价:** $558 (+31.6% upside vs current $424)
- **高 / 低:** $612 / $437
- **买入 / 持有 / 卖出:** 26 / 5 / 1
- **分析师数量:** 15 (上一季度), 87 历史总数

## 额外财报电话会议洞察

### 1. 2026_revenue_growth

**主张:** Vertex anticipates total company revenue growth of 8% to 9% in 2026.

**证据 (会议记录):** "We expect full year 2026 total company revenue to be in the range of $12.95 billion to $13.1 billion, representing 8% to 9% growth versus the prior year."

**数据:** 8%, 9%, $12.95 billion, $13.1 billion

### 2. non_CF_revenue_contribution

**主张:** Vertex expects a $500 million or greater revenue contribution from non-CF products in 2026.

**证据 (会议记录):** "This outlook anticipates continued solid performance from our CF franchise and a $500 million or greater revenue contribution from non-CF products, including greater volumes of patient infusions for CASGEVY and a ramp of JOURNAVX prescriptions."

**数据:** $500 million

### 3. journavx_prescription_growth

**主张:** Vertex expects JOURNAVX prescriptions to more than triple in 2026 compared to 2025.

**证据 (会议记录):** "In 2026, we expect to more than triple the number of JOURNAVX prescriptions compared to approximately 550,000 written in 2025."

**数据:** 550,000, 2025

### 4. operating_expense_guidance

**主张:** Vertex anticipates combined non-GAAP operating expenses to be in the range of $5.65 billion to $5.75 billion for 2026.

**证据 (会议记录):** "Additionally, we expect combined non-GAAP operating expenses to be in the range of $5.65 billion to $5.75 billion as we continue to invest in our late-stage clinical pipeline and commercial buildouts in support of new launches and revenue diversification, particularly for JOURNAVX in acute pain and for renal."

**数据:** $5.65 billion, $5.75 billion

### 5. effective_tax_rate_guidance

**主张:** Vertex anticipates its non-GAAP effective tax rate to be in the range of 19.5% to 20.5% for 2026.

**证据 (会议记录):** "We anticipate our non-GAAP effective tax rate to be in the range of 19.5% to 20.5% for 2026 as we do not expect a repeat of the onetime tax benefits we experienced in 2025."

**数据:** 19.5%, 20.5%, 2026, 2025

### 6. renal_franchise_potential

**主张:** Vertex anticipates that the renal franchise will ultimately rival the scale of our CF business.

**证据 (会议记录):** "We anticipate that the renal franchise will ultimately rival the scale of our CF business, and we're seeking to bring the best elements of our success in CF to these kidney disease areas."

**数据:** —


---

*数据来源：FMP (实时查询，2026-05-03)，Q4 FY2025 财报电话会议记录 (由 Gemini 2.0 Flash 翻译成中文)。本工具为教育目的，不构成投资建议。*